Literature DB >> 26168486

Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.

Toshiyuki Tsunoda1, Shuhei Ishikura1, Keiko Doi1, Yuri Iwaihara2, Hiromasa Hidesima2, Hao Luo2, Yumiko Hirose1, Senji Shirasawa3.   

Abstract

BACKGROUND/AIM: Oncogenic mutations in the KRAS gene are critically involved in many human tumors but drugs targeting oncogenic KRAS have not yet been clinically developed. Herein, we established a three-dimensional floating (3DF) culture system for screening drugs that target KRAS-mediated signaling molecules.
MATERIALS AND METHODS: HKe3 cells, derived from colorectal cancer HCT116 cells and disrupted at mutated (mt) KRAS gene, were infected with a retrovirus expressing wild-type (wt) KRAS or mtKRAS to establish HKe3-derived cells expressing wtKRAS or mtKRAS. Established cells were cultured in 96-well plates with an ultra-low attachment surface and round bottom for 3DF culture.
RESULTS: HKe3-wtKRAS and HKe3-mtKRAS cells in 3DF culture rapidly assembled into respective single spherical structures (spheroids). Furthermore, mtKRAS but not wtKRAS expression inhibited luminal apoptosis in spheroids indicating that the 3DF culture was compatible with the 3D matrigel culture.
CONCLUSION: This 3DF culture system could be useful for screening drugs that target KRAS-mediated signaling molecules. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  3-dimensional floating culture; KRAS; colorectal cancer; drug screening

Mesh:

Substances:

Year:  2015        PMID: 26168486

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation.

Authors:  Haruna Okamoto; Taiji Matsukawa; Satoshi Doi; Toshiyuki Tsunoda; Yuuga Sawata; Madoka Naemura; Koichiro Ohnuki; Senji Shirasawa; Yojiro Kotake
Journal:  Mol Cell Biochem       Date:  2017-09-21       Impact factor: 3.396

2.  ANRIL regulates the proliferation of human colorectal cancer cells in both two- and three-dimensional culture.

Authors:  Madoka Naemura; Toshiyuki Tsunoda; Yasutoshi Inoue; Haruna Okamoto; Senji Shirasawa; Yojiro Kotake
Journal:  Mol Cell Biochem       Date:  2015-12-26       Impact factor: 3.396

3.  The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.

Authors:  Juri Ogishima; Ayumi Taguchi; Akira Kawata; Kei Kawana; Mitsuyo Yoshida; Yuki Yoshimatsu; Masakazu Sato; Hiroe Nakamura; Yoshiko Kawata; Akira Nishijima; Asaha Fujimoto; Kensuke Tomio; Katsuyuki Adachi; Takeshi Nagamatsu; Katsutoshi Oda; Tohru Kiyono; Yutaka Osuga; Tomoyuki Fujii
Journal:  BMC Cancer       Date:  2018-12-03       Impact factor: 4.430

4.  Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation.

Authors:  Theodosia Charitou; Sriganesh Srihari; Miriam A Lynn; Mohamed-Ali Jarboui; Erik Fasterius; Max Moldovan; Senji Shirasawa; Toshiyuki Tsunoda; Marius Ueffing; Jianling Xie; Jin Xin; Xuemin Wang; Christopher G Proud; Karsten Boldt; Cristina Al-Khalili Szigyarto; Walter Kolch; David J Lynn
Journal:  Br J Cancer       Date:  2019-05-28       Impact factor: 7.640

5.  A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells.

Authors:  Yuuga Sawata; Taiji Matsukawa; Satoshi Doi; Toshiyuki Tsunoda; Nagisa Arikawa; Natsumi Matsunaga; Koichiro Ohnuki; Senji Shirasawa; Yojiro Kotake
Journal:  Mol Cell Biochem       Date:  2019-08-22       Impact factor: 3.396

6.  Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1.

Authors:  Palanivel Kandasamy; Inti Zlobec; Damian T Nydegger; Jonai Pujol-Giménez; Rajesh Bhardwaj; Senji Shirasawa; Toshiyuki Tsunoda; Matthias A Hediger
Journal:  Mol Oncol       Date:  2021-06-18       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.